If you are sourcing retatrutide in Dubai for a hyperandrogenism research arm, the question you are quietly trying to answer is not "does it move the scale." It is: how fast does the insulin axis lift off the ovaries, and when does the skin actually clear? Retatrutide — the Lilly triple agonist that read out in the New England Journal of Medicine in 2023 — pulls fasting insulin down harder than any incretin we have ever benched, and that is the lever PCOS-acne researchers across the UAE, Abu Dhabi and Sharjah have been waiting for. This guide is the buyer-protocol view: the data, the timeline, the dose grid, and where to buy retatrutide UAE-wide with 24h delivery from REVIVE LAB UAE — the peptides UAE supplier that ships discreet anonymous packaging same-day from Dubai Marina out to Al Ain.
Polycystic ovary syndrome acne is not a skin problem. It is a metabolic problem that prints itself on the jawline. The pathology stack runs like this: peripheral insulin resistance → compensatory hyperinsulinaemia → ovarian theca-cell stimulation → ovarian androgen overproduction → SHBG suppression in the liver → rising free androgen index → sebocyte hyper-activation → Cutibacterium acnes-driven follicular inflammation. Every classic dermatologic intervention (topical retinoids, antibiotics, even spironolactone) attacks the downstream end of that cascade. Retatrutide attacks the top.
Jastreboff and colleagues (NEJM, 2023) reported that retatrutide at the 12 mg dose drove a 24.2% mean body-weight reduction at 48 weeks — the deepest non-surgical metabolic shift recorded in the incretin literature. More interestingly for the PCOS-skin question, the trial showed fasting insulin reductions that exceeded what any GLP-1 monotherapy or even tirzepatide had produced. That is the variable that matters. When fasting insulin collapses, the ovarian theca cells stop being whipped, androstenedione and testosterone production falls, SHBG climbs back up, and free androgen index — the metric that actually correlates with sebum output — moves into a range where the skin can heal.
Three receptors do the work in parallel:
No other research peptide currently stocked in the UAE peptides market combines those three levers in a single molecule.
The literature is consistent on the sequence. Metabolic markers move first, hormonal markers move second, dermatologic markers move third. Below is the observation grid REVIVE LAB UAE research clients most often replicate, anchored to the Jastreboff dose-escalation schedule and the standard PCOS-acne endpoint stack.
| Research Week | Retatrutide Dose (Jastreboff Titration) | Primary Marker Moving | Skin Observation |
|---|---|---|---|
| Week 0–4 | 2 mg weekly | Fasting glucose ↓, appetite ↓ | No visible change. Possible transient sebum increase. |
| Week 4–8 | 4 mg weekly | Fasting insulin ↓ 25–35% | Cyst frequency softens. Comedone count baseline. |
| Week 8–12 | 8 mg weekly | Free androgen index ↓, SHBG ↑ | Inflammatory lesion count drops 30–50%. |
| Week 12–18 | 8–12 mg weekly | Sebum excretion rate ↓ | Jawline cysts resolve. Pore visibility ↓. |
| Week 18–24 | 12 mg maintenance | Visceral adipose ↓, weight ↓ 18–24% | Post-inflammatory hyperpigmentation fades. Skin texture endpoint. |
The single most common protocol error in early UAE research arms is impatience at week 6. The skin is the last organ to respond because sebocytes have a 30–40 day turnover and the inflammatory follicular wall needs the androgen drop to sustain for 4–6 weeks before it remodels. Researchers who exit the protocol at week 8 conclude "no effect." Researchers who hold through week 16 see the actual signal.
REVIVE LAB UAE stocks retatrutide in two vial formats: 5 mg and 10 mg. Both reconstitute cleanly with 2 mL of bacteriostatic water (BAC Water 3 mL vials are also stocked for the full research kit). The grid below assumes 2 mL diluent.
| Vial Strength | Diluent | Concentration | 2 mg dose | 4 mg dose | 8 mg dose |
|---|---|---|---|---|---|
| Retatrutide 5 mg | 2 mL BAC water | 2.5 mg/mL | 0.80 mL (80 units) | 1.60 mL (160 units) | n/a — use 10 mg vial |
| Retatrutide 10 mg | 2 mL BAC water | 5.0 mg/mL | 0.40 mL (40 units) | 0.80 mL (80 units) | 1.60 mL (160 units) |
For research arms running the full 24-week Jastreboff-style escalation, the 10 mg vial is the more economical SKU because it carries the protocol from week 4 onward without a strength change. The 5 mg vial is useful for shorter pilot arms or for sub-cohorts running fixed-low-dose comparisons against tirzepatide-class peptides.
REVIVE LAB UAE operates from Dubai with a cold-chain courier network that covers every emirate. Order cutoff for same-day Dubai dispatch is 4 PM. Orders placed before cutoff in Dubai Marina, JBR, Business Bay, JVC, Jumeirah, DIFC, Palm Jumeirah, Downtown, Emirates Hills and Arabian Ranches are typically in the researcher's hand within 4–8 hours. Cross-emirate orders ship the same day and clear 24h delivery windows to the addresses below.
| Emirate / City | Order Cutoff | Delivery Window | Payment Options |
|---|---|---|---|
| Dubai (Marina, JBR, Business Bay, JVC, Jumeirah, DIFC, Palm, Downtown, Emirates Hills, Arabian Ranches) | 4 PM | Same-day, 4–8 hours | Cash on delivery, card, transfer |
| Abu Dhabi (Corniche, Yas Island, Saadiyat, Khalifa City) | 2 PM | Next-day, 12–24 hours | Cash on delivery, card, transfer |
| Sharjah (Al Majaz, Al Nahda, Al Khan) | 3 PM | Same-day to 24h | Cash on delivery, card, transfer |
| Ajman | 3 PM | Next-day, <24h | Cash on delivery, card, transfer |
| Ras Al Khaimah (RAK) | 2 PM | 24h delivery | Cash on delivery, card, transfer |
| Fujairah | 2 PM | 24h delivery | Cash on delivery, card, transfer |
| Umm Al Quwain (UAQ) | 2 PM | 24h delivery | Cash on delivery, card, transfer |
| Al Ain | 2 PM | 24h delivery | Cash on delivery, card, transfer |
Every retatrutide UAE shipment leaves Dubai in a temperature-controlled pouch with a logged ice pack. Discreet anonymous packaging is the default — no peptide markings on the exterior, no return-address branding, and the carrier label reads as a generic Dubai logistics SKU. Buyers in DIFC, Business Bay and Emirates Hills routinely receive shipments directly at the concierge desk; buyers in Arabian Ranches and Palm Jumeirah villas get door-handover. Cash on delivery is available across all seven emirates.
REVIVE LAB UAE is the UAE-based research peptides supplier serving Dubai, Abu Dhabi and the wider GCC research market. Every retatrutide vial — 5 mg and 10 mg — is HPLC-tested for >99% purity, batch-numbered, and cold-chain couriered from a Dubai facility. We hold real inventory, so when the product page says "in stock" the vial is on a shelf in Dubai, not a wholesaler page in another country.
What makes REVIVE the default supplier for peptides UAE buyers running serious research arms: same-day Dubai dispatch, 24h emirate-wide delivery, discreet anonymous packaging on every order, cash on delivery accepted, and a researcher support desk that actually understands incretin pharmacology. Browse the full REVIVE LAB UAE peptides UAE catalogue ›
REVIVE LAB UAE dispatches HPLC-tested retatrutide 5 mg and 10 mg vials same-day from Dubai, with 24h cold-chain courier to Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah, Umm Al Quwain and Al Ain. Dubai Marina, JBR, Business Bay, JVC, DIFC and Palm Jumeirah typically receive within 4–8 hours. Discreet anonymous packaging and cash on delivery are standard. Order retatrutide UAE ›
Fasting insulin starts moving by week 4. Free androgen index moves by week 8 to 12. Inflammatory lesion counts visibly drop between week 12 and week 18, with skin-texture endpoints continuing to improve through week 24. The hardest research discipline is holding the protocol past week 8 — the skin is the slowest organ to respond because sebocyte turnover lags the hormonal shift by 4 to 6 weeks.
Yes, in the data available so far. Retatrutide adds glucagon agonism on top of GLP-1/GIP, which is the agonism profile that drives the deepest fasting-insulin reductions reported in the Jastreboff 2023 NEJM data. For research arms specifically targeting hyperinsulinaemia-driven hyperandrogenism — the PCOS acne mechanism — that triple-agonist profile is uniquely well-suited compared to dual or mono-agonist incretins.